 PRINCETON, N.J., Sept. 16, 2021 PRNewswire -- Soligenix, Inc. Nasdaq: SNGX Soligenix or the Company, a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that following the validation of synthetic hypericins biologic activity in the positive pivotal Phase 3 FLASH Fluorescent Light Activated Synthetic Hypericin study in cutaneous T-cell lymphoma CTCL, as well as positive proof-of-concept PoC demonstrated in a small Phase 12 pilot study in mild-to-moderate psoriasis patients, the Company will be expanding this novel therapy under the research name SGX302 into psoriasis, a large and underserved market with a significant unmet medical need. 